Model Systems for Fragile X Pre-Mutation and Primary Ovarian Insufficiency (FX-POI) (R21)

Post Date

March 9th 2011

Application Due Date

June 1st 2012

Funding Opportunity Number

PAR-11-137

CFDA Number(s)

93.865

Funding Instrument Type(s)

Grant

Funding Activity Categories

Health
Income Security and Social Services

Eligibility Categories

State Governments
County Governments
City or Township Governments
Special District Governments
Independent School Districts
Public and State Controlled Institutions of Higher Education
Federally Recognized Native American Tribal Governments
Public Housing Authorities or Indian Housing Authorities
Non-Federally Recognized Native American Tribal Organizations
Non-Profits With 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Non-Profits Without 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Private Institutions of Higher Education
For-Profit Organizations (Except Small Businesses)
Small Businesses
Other

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Foreign (non-U.S.) components of U.S. Organizations are allowed.

Funding

• Award Range:

  $None - $200000

Grant Description

The purpose of this funding opportunity announcement (FOA) is to stimulate the development of new model systems and/or the thorough characterization of the ovarian phenotype of existing models of fragile X associated premature ovarian insufficiency (FX-POI). New and well-characterized models of FX-POI will help us to answer fundamental questions about the role of the FMR1 repeat expansion in ovarian function and reproductive aging, and allow the field to advance into evidence based clinical research on fragile X pre-mutation carriers who are at risk for POI.

Contact Information

• Agency

  Department of Health and Human Services

• Office:

  National Institutes of Health

• Agency Contact:

  NIH OER Webmaster
  FBOWebmaster@OD.NIH.GOV
  

• Agency Mailing Address:

  If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

• Agency Email Address:

  FBOWebmaster@OD.NIH.GOV

• More Information:

  http://grants.nih.gov/grants/guide/pa-files/PAR-11-137.html